CHICMAX (02145) has announced that it recently signed a strategic cooperation framework agreement with Suzhou Kintor Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kintor Pharmaceutical Limited (listed on the Hong Kong Stock Exchange, stock code: 9939). The agreement includes exclusivity clauses in the cosmetics field and pertains to the rapid commercialization of the cosmetic ingredient KT-939, which is known for its skin-whitening and spot-removing effects. Under the framework agreement, CHICMAX and Suzhou Kintor will collaborate on the registration of KT-939 as a new cosmetic ingredient in China, as well as the registration of cosmetic products using KT-939 as a core component. The partnership will also involve joint research, development, and customization of functional ingredients, with the goal of creating an industry-leading "strongest domestic whitening product" based on KT-939. CHICMAX plans to leverage the development, registration, and application of KT-939 to further diversify its product portfolio, enhance its scientific research capabilities in advanced cosmetic ingredients and product efficacy, and strengthen its leadership in the functional whitening and spot-removing cosmetics market.